STI Stock Trade Intelligence
PCK

PAINCHEK LTD

Health Care · ASX:PCK
$0.0680
▼ -1.45%
Market cap
$14M
Turnover
$16,442
Last price
$0.0680
Day change
-1.45%
Announcements
11
Range, past year
Open 0.042 · Low 0.033 · Now 0.068 · High 0.350
Open PCK in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

PCK momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-11-16.
Momentum quality
26/100
Wyckoff phase
Accumulation5d
Trend stage
Neutral
1 Day
-1.4%
1 Week
-2.9%
1 Month
-26.9%
1 Year
-81.4%
RSI
39
Avg daily range
7.9%

PAINCHEK LTD scores 26 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.

On the Wyckoff cycle it sits in Accumulation, where it has been for 5 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.

Against the wider market it is currently underperforming and the institutional accumulation signal reads low.

Points to watch
  • 60d drawdown -46.4%
  • High volatility (ATR 7.9%)
  • Thin liquidity
  • Risk rating: Very High
  • Composite downside risk elevated
PCK appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

PCK announcements

Recent price-sensitive releases.
  • 2026-10-28 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
  • 2026-10-27 PainChek wins 1,800-licence UK contract with Hallmark Progress Report
  • 2026-10-13 PainChek expands Sabra contracts to 23 US communities Progress Report
  • 2026-08-28 Appendix 4E and Financial Report Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report | Notice of Meeting - Other
  • 2026-07-29 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
  • 2026-07-22 PainChek receives $1.123 million R&D tax incentive refund
  • 2026-07-20 US MedTech leader Karen Holzberger appointed CEO
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.